cov

Thailand's National Health Security Office (NHSO) has so far paid 1.509 billion baht ($45.65 million) as compensation to 12,714 people who developed side-effects after they received Covid-19 vaccines.

A new study has found that moderate levels of physical activity can protect against severe outcomes from COVID-19 such as hospitalizations, ICU admissions, and death.

Despite the significant increase in the generation of SARS-CoV-2 contaminated domestic and hospital wastewater, little is known about the ecotoxicological effects of the virus or its structural components in freshwater vertebrates. In this context, this ...

Comparisons with myocarditis rates following infection now irrelevant as vaccination no longer prevents infection.

This cohort study assesses the association between the single-dose COVID-19 BNT162b2 vaccination regimen and myocarditis risk among vaccinated adolescents in Hong Kong before and after the single-dose policy.

Background The emergence of COVID-19 requires alternative treatments based on the reuse of drugs as a strategy to prevent the progression of the disease in patients infected with SARS-COV-2. The goal was to evaluate the use of ivermectin in mild stage outpatients to heal and / or reverse the progression of COVID-19 disease towards the development of moderate or severe stages. Methods Cluster Assigned Clinical Trial (2:1) in outpatients, n = 234. The subjects were divided into experimental (EG: n = 110) and control groups (CG: n = 62). The EG received ivermectin orally 4 drops of 6 mg = 24 mg every 7 days for 4 weeks. All participants were diagnosed by positive RT-PCR for COVID-19 and were evaluated by clinical examination, at the beginning and the end of protocol. Data analyzed were applied the proportion, bivariate, and logical regression tests with level significance p 0·05. This study was registered at [ClinicalTrials.gov][1] Identifier [NCT04784481][2]. Findings Both groups were similar in age, sex, and comorbidities (EG: 56F, median age= 40·0, range: 18·0 - 75·0; CG: 34F, median age = 37·5, range: 18·0 - 71·0). A significant reduction in the symptom numbers was observed in the EG when the medical examination was performed from 5th to 9th days, after starting treatment ( p = 0·0026). Although, medical examination from 10th to 14th day, showed a progressive reduction of the percentage symptom numbers, these were not significative in both groups. A higher proportion of medical release was observed in EG (98·2%) vs CG (87·1%) ( p = 0·003). EG showed 8 times more chance of receiving medical release than CG (OR 7·99, 95% CI: 1·64 −38·97, p = 0·003). The treatment effect with ivermectin to obtain medical release was analyzed by the logistic regression model based in the following control variables: sex, age, and comorbidities. Then, the chance to obtain medical release was maintained in EG (OR 10·37, 95% CI: 2·05 - 52·04, p = 0·005). Interpretation Treatment with ivermectin in outpatients with mild stage COVID-19 disease managed to slightly reduce the symptom numbers. Also, this treatment improved the clinical state to obtain medical release, even in the presence of comorbidities. The treatment with ivermectin could significantly prevent the evolution to serious stages since the EG did not present any patient with referral to critical hospitalization. Clinical Trials registry number is [NCT04784481][2] Funding Ministry of Public Health. Tucumán, Argentina. Evidence before this study Currently there are no specific therapies approved for COVID-19 treatment by the FDA, that is why different repositionable drugs are being studied in clinical trials and compassionate use protocols based on in vitro activity. ivermectin is a broad spectrum antiparasitic agent that has been shown to have antiviral activity against a wide range of viruses. A study by Caly et al. (2020) suggested thatnuclear transport inhibitory activity of ivermectin may be effective against SARS-CoV-2. Since the publication of that work, numerous clinical trials were started to study ivermectin potential for COVID-19 treatment. At the end of March 2021, there were about 60 studies registered in , and 43 studies listened about the safety and effectiveness of ivermectin in COVID-19 patients, for treatment and prophylaxis. Most of these studies are from developing countries, which shows the need of emerging economies to find alternative therapies to contain the spread of the disease and the collapse of health systems. Added value of this study We found that an early intervention with ivermectin has impacted on the score of symptoms related to COVID-19 in ambulatory patients, between the 5th and 9th day. The patients who received the treatment changed from score 2 to score 1 in the WHO ordinal scale. In any case, patients evolved to higher scores. Also the treatment increased the probability to obtain medical release, even in the presence of comorbidities. Implications of all available evidence According to the COVID-19 Treatment Guidelines by the NIH, most trials have several limitations. It needs results from adequately powered and well-designed clinical trials to provide evidence-based guidance on the role of ivermectin in the treatment of COVID-19. However, our study shows overlaps in benefits with other authors, and taking together, these results are encouraging for further study about repurposing ivermectin for the treatment of COVID-19. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial NCT04784481 ### Clinical Protocols ### Funding Statement Ministery of Health, Tucuman, Argentina. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Board Status: Approved Approval Number: 054/2020 Board Name: Independent Ethical Comitee. Board Affiliation: ReNIS (National Register in Health Research) Argentina. Number 0032 All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Data Sharing Statement Data available:Yes Data types:Participant data with identifiers How to access data:E-mail request for data: mperal{at}fm.unt.edu.ar - Dr. Maria Peral de Bruno Who can access the data:Researchers whose proposed use of the data has been approved Types of analyses:for a specified purpose Mechanisms of data availability:with investigator support [1]: http://ClinicalTrials.gov [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04784481&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F30%2F2021.03.29.21254554.atom

To evaluate the difference in mortality of patients treated with ivermectin vs patients treated with remdesivir with COVID-19 in United States using T…

For hospitalized patients already taking other proven COVID-19 drugs, pill further reduces chance of death

Forty-six nursing home residents who had received their first dose of Pfizer-BioNTech’s fast-tracked vaccination against COVID-19 at the beginning of January had died by the end of the month, Spanish…

Pfizer Documents Produced by the FDA in FOIA Litigation Court Documents Pfizer's Documents Download Multiple Documents

An unresolved issue of SARS-CoV-2 disease is that patients often remain positive for viral RNA as detected by PCR many weeks after the initial infection in the absence of evidence for viral replication. We show here that SARS-CoV-2 RNA can be reverse-transcribed ...

A scientific study conducted by scientists from the U.S Food and Drug Administration and the Centers for Disease Control, has found the the Pfizer Covid-19 inje

The world’s first plant-derived Covid-19 vaccine was cleared for use in Canada, creating a novel immunization to combat the virus from a unit of Mitsubishi Chemical Holdings Corp. and Philip Morris International.

can't vouch for this site, but food for thought.

Recent studies focus renewed attention on the ongoing debate about the importance of infection-acquired immunity and the extent to which it should be taken into account in public health policy.

Can mRNA disrupt the drug industry? Messenger RNA technology promises to turn our bodies into medicine-making factories. But first Moderna—and a long list of old and new competitors—needs to overcome some major scientific challenges

In this paper, we provide the first data characterizing the actual proteins produced by mouse and human cells in culture that had been incubated up to 30 minutes with the commercial vaccine produced by Moderna (i.e., Spikevax). The mRNA vaccine continues to produce proteins up to 12-14 days after introduction to the cells. . . . In communications with Moderna and Pfizer-BioNTech regarding the proteins expressed by their synthetic mRNA vaccines, each company’s medical information group disclosed that that they had not examined the protein dynamics more than 48 hours post-transfection in cell culture.

Vaccines have been developed at “warp speed” to combat the COVID-19 pandemic caused by the SARS-CoV-2 coronavirus. Although they are considered the best approach for preventing mortality, when assessing the safety of these vaccines, pregnant ...

In the province of Reggio Emilia, Northern Italy, we observed four cases of AHA following SARS-CoV-2 immunization with mRNA BNT162b2 vaccine (produced by Pfizer-BioNTech) during the first eight months from the beginning of SARS-CoV-2 vaccination campaign. During this time frame, 235,597 people received at least one dose of BNT162b2 vaccine.

The U.S. and U.K. are in the very early stages of applying existing vaccine-injury programs to hundreds of claims of injury alleged from Covid-19 shots.

Larazotide helps rid body of spike protein .

Most of the states across America have already dropped the well-known pandemic measures while the rest of the states are considering to do it in near future as the country is entering from pandemic to endemic phase with Covid-19. This transition seems possible since majority of Americans are now vaccinated against Covid-19 or have developed …

Blinded by bias, some reporters struggle to see misinformation that buttresses their own bigotry

Among numerous point mutation differences between the SARS-CoV-2 and the bat RaTG13 coronavirus, only the 12-nucleotide furin cleavage site (FCS) exceeds 3 nucleotides. A BLAST search revealed that a 19 nucleotide portion of the SARS.Cov2 genome encompassing the furing cleavage site is a 100% complementary match to a codon-optimized proprietary sequence that is the reverse complement of the human mutS homolog (MSH3). The reverse complement sequence present in SARS-CoV-2 may occur randomly but other possibilities must be considered. Recombination in an intermediate host is an unlikely explanation. Single stranded RNA viruses such as SARS-CoV-2 utilize negative strand RNA templates in infected cells, which might lead through copy choice recombination with a negative sense SARS-CoV-2 RNA to the integration of the MSH3 negative strand, including the FCS, into the viral genome. In any case, the presence of the 19-nucleotide long RNA sequence including the FCS with 100% identity to the reverse complement of the MSH3 mRNA is highly unusual and requires further investigations.

Reference is made to the Request for Comments and Advice submitted 04 February 2021 regarding Pfizer/BioNTech’s proposal for the clinical and post-authorization safety data package for the Biologics License Application (BLA) for our investigational COVID-19 Vaccine (BNT162b2). Further reference is made to the Agency’s 09 March 2021 response to this request, and specifically, the following request from the Agency.